Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Stock data | 2023 | Change |
---|---|---|
Price | $39.42 | N/A |
Market Cap | $251.86B | N/A |
Shares Outstanding | 6.39B | -0.17% |
Employees | 103.61K | N/A |
Shareholder Equity | 33.26B | 3.90% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 3.53 | N/A |
P/B Ratio | 7.57 | N/A |
P/FCF | 18.64 | N/A |
Dividends | 2023 | Change |
---|---|---|
Dividend Yield | 3.56% | N/A |
Dividend per share | 1.4027 | N/A |
Dividend Payout Ratio | 0.6142 | N/A |
Growth | 2023 | Change |
---|---|---|
ROIC | 0.1886 | N/A |
CAPEX | -4.21B | N/A |
Return on Equity | 0.4387 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $71.37B | N/A |
Earnings | $14.59B | N/A |
Free Cash Flow | $13.52B | N/A |
Gross Margin | 0.7294 | N/A |
Operating Margin | 0.2547 | N/A |
Net income margin | 0.2045 | N/A |
FCF Margin | 0.1894 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $106.82B | N/A |
Total Debt | $36.35B | N/A |
Cash on Hand | $12.41B | N/A |
Debt to Equity | $2.03 | -1.92% |
Cash to Debt | 0.3414 | -7.21% |
Current Ratio | $1.35 | 8.53% |